ENTL Entelos Regs

Entelos Inc.
21 February 2008

For immediate release:


                                 ENTELOS, Inc.

                          ("Entelos" or "the Company")

                 Entelos Announces Agreement with PDL Biopharma

FOSTER CITY, California, February 21, 2008 - Entelos, Inc. (LSE:ENTL) a leading
life sciences company building predictive computer models of human physiology
and "virtual patients" for drug discovery and development, announced today that
PDL Biopharma ("PDL") has signed an agreement with Entelos to conduct in silico
research and "virtual clinical trials".  The research is expected to take two
months and is focused on identifying primary endpoints, patient types, and
optimal doses to support one of PDL's antibody development programs.

"We are pleased to add PDL to our growing list of biotechnology customers,"
commented James Karis, president and CEO of Entelos. "Clinical trial simulations
are one of the most powerful and important applications of our Physiolab
platforms. Simulating clinical trials prior to conducting them can significantly
reduce the risk, time, and overall cost of a drug program, especially when
companies are faced with key decisions about selecting the right dose and
patient types upfront. We look forward to making a positive impact at PDL and
providing them useful information to support their pipeline."

For further information please contact:
Entelos, Inc.
James Karis, President and CEO                         Tel: +1 650 572 5400

Jill Fujisaki, VP Investor Relations
Evolution Securities
Bobbie Hilliam                                         Tel: +44 (0)20 7071 4300

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson                      Tel +44 (0) 20 7466 5000



About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.





                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRATMMTTMMTTTLP

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024